Compare Adaptive Biotechnologies Corp (ADPT) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Xylem, Inc. — how do they compare? Adaptive Biotechnologies Corp trades at $24.99 (market cap $4.04B), while Xylem, Inc. trades at $121.57 (market cap $28.76B). The key difference: Xylem, Inc. is far larger — about 7.1× Adaptive Biotechnologies Corp's market cap, and Xylem, Inc. pays a 1.4% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | XYL | |
|---|---|---|
Market Cap | $4.04B | $28.76B |
Sector | Health | Industrials |
52-Week High | $25.45 | $152.95 |
52-Week Low | $12.30 | $106.34 |
Enterprise Value | $4.10B | $30.54B |
Dividend Yield | — | 1.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $24.94, down 2.0% today but near its 52-week high. The stock shows a bullish technical trend with improving fundamentals, including 49% MRD revenue growth and narrowing losses. A recent 4:1 reverse stock split and planned business separation aim to unlock value, with analyst consensus leaning bullish.
Outlook is cautiously optimistic due to strong revenue growth and margin expansion, but risks persist from ongoing net losses and competitive pressures. The stock offers potential upside to the $25.50 consensus target if execution continues improving, yet volatility may remain until profitability is achieved.
XYL trades at $121.59, up 0.33% today, with a bullish technical signal from moving averages and strong quarterly earnings beats. Revenue grew to $9.04B in 2025, with net income margin expanding to 10.59%. Recent acquisitions like Cornell Pump and Roper Pump aim to strengthen its industrial water technology presence, while AI-driven demand for water-treatment equipment supports growth.
The outlook is positive, with a consensus price target of $150.43 implying 24% upside, backed by margin expansion and strategic acquisitions. Risks include execution of integration and potential revenue delays from electric metering projects, as noted in Q2 2026 results. Analyst sentiment is mixed but leans bullish, with 47.5% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
